Research Shows Link Between Patient Recruitment Methods and Retention
Research from MediciGlobal shows that patients who actively sought clinical trial involvement through its online recruitment model had a 38% lower relative risk of drop out across four studies compared to those who were recruited by sites, with divergence across visits.
Research from MediciGlobal shows that patients who actively sought clinical trial involvement through its online recruitment model had a 38% lower relative risk of drop out across four studies compared to those who were recruited by sites, with divergence across visits. The primary outcome for the meta-analysis measure was retention rates of subjects recruited comparing the two methods of engagement, online versus site databases. A secondary outcome was retention rates across all study visits to determine divergence patterns between the two groups.
The firm noted in a press release that higher retention levels of subjects actively engaged in seeking out a clinical trial compared to those who were passively engaged via the physician or study staff may be related to different motivations between the groups of patients. This may be due to the company's online process in which patients seeking the study online must also undergo a comprehensive vetting procedure. The company says additional research is necessary to further understand the drivers of these differences.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.
Phase III Trial Data Show Subcutaneous Pembrolizumab as Noninferior to IV Keytruda
March 31st 2025Subcutaneous administration of pembrolizumab with chemotherapy demonstrated a nearly 50% reduction in patient chair and treatment room time while maintaining efficacy and safety endpoints compared to intravenous Keytruda.
Phase II ALPACA Trial Shows Lepodisiran Produces Significant, Sustained Lipoprotein(a) Reductions
March 31st 2025Eli Lilly’s lepodisiran, an investigational siRNA therapy, achieved significant and durable reductions in lipoprotein(a) levels, a major genetic risk factor for cardiovascular disease.
